The journey of Takeda’s gout med Uloric—which turned rocky in recent years—has come to an end in the U.S. | Following some ...

By August or September of this year, Petersen said he expects “basically half” of the company’s $8 billion in manufacturing ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...

As users continue to leave X (formerly Twitter) en masse, many in favor of the newer Bluesky platform, the European Medicines ...

Diabetes and weight management drugs dominated game-day NFL advertising during the regular season, with TV outcomes company ...

This week on “The Top Line,” we break down the biggest stories out of JPM, from J&J’s blockbuster acquisition of ...

In the latest twist in its efforts to wrap up years of high-profile opioid litigation, the billionaire family behind the ...

Department of Health and Human Services (HHS) secretary nominee Robert F. Kennedy Jr. plans to continue to receive referral fees from a law firm that is suing pharma powerhouse Merck & Co. | ...

Some six and a half years since its debut, Servier’s U.S. arm has made good on its oncology growth ambitions while managing to stay true to its patient-centric ethos along the way. | Some six and a ...

One of the 30-second spots taps into the intensity of hit shows like “Game of Thrones.” It starts with a medieval royal preparing to go to war in the name of colorectal cancer screening, declaring, ...

The Preeclampsia Foundation has found a formula for closing the maternal health equity gap: Mix one part equity-forward preeclampsia education with one part low-dose aspirin prophylaxis and voilà, you ...